Overview

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Status:
Terminated
Trial end date:
2019-03-30
Target enrollment:
Participant gender:
Summary
To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Phase:
Phase 3
Details
Lead Sponsor:
Encore Dermatology, Inc.
Promius Pharma, LLC
Collaborator:
Prosoft Clinical
Treatments:
Betamethasone